Standout Papers

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, ra... 2018 2026 2020 2023 218
  1. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study (2018)
    Florence Duffaud, Olivier Mir et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

Recent Advances in 3D Printing of Smart Scaffolds for Bone Tissue Engineering and Regeneration
2024 Standout
Bispecific antibodies: advancing precision oncology
2024 Standout
1 intermediate paper

Works of Esma Saâda being referenced

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
2024
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
2018 Standout

Author Peers

Author Last Decade Papers Cites
Esma Saâda 484 370 153 157 70 821
Sagus Sampath 431 335 71 114 49 833
Siddhartha Laskar 352 334 86 184 56 795
Jiřı́ Petera 362 332 64 276 103 925
F Eschwège 242 342 345 316 32 863
Marián Švajdler 264 277 39 222 98 788
Milan Vošmik 242 252 169 285 78 740
Myron Arlen 492 348 37 227 48 894
Alexander T. Falk 469 314 35 226 56 910
Albiruni Abdul Razak 254 416 139 130 36 705
Laura Botta 243 273 58 105 54 736

All Works

Loading papers...

Rankless by CCL
2026